<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16(10)</volume><submitter>Wang HC</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>The extent of short-acting Beta-2-agonist (β&lt;sub>2&lt;/sub>-agonist) (SABA) use across Asian countries is not well documented. As part of the SABA use IN Asthma (SABINA) III study, we assessed SABA prescriptions and clinical outcomes in patients with asthma from Asia.&lt;h4>Methods&lt;/h4>This cross-sectional study recruited patients (aged ≥12 years) with asthma from 8 Asian countries. Data on disease characteristics and asthma treatments were collected using electronic case report forms. Patients were classified by practice type (primary or specialist care) and investigator-defined asthma severity (per Global Initiative for Asthma [GINA] 2017 recommendations). The association of SABA prescriptions with clinical outcomes was analyzed using multivariable regression models.&lt;h4>Resu</pubmed_abstract><journal>The World Allergy Organization journal</journal><pagination>100823</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10587767</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Evaluation of short-acting Beta-2-agonist prescriptions and associated clinical outcomes: Findings from the SABA use IN Asthma (SABINA) study in Asia.</pubmed_title><pmcid>PMC10587767</pmcid><pubmed_authors>Lim HF</pubmed_authors><pubmed_authors>Yang L</pubmed_authors><pubmed_authors>Theerakittikul T</pubmed_authors><pubmed_authors>Yu-Lin AB</pubmed_authors><pubmed_authors>Diaz DV</pubmed_authors><pubmed_authors>Wang HC</pubmed_authors><pubmed_authors>Yoo KH</pubmed_authors><pubmed_authors>Djajalaksana S</pubmed_authors><pubmed_authors>Beekman MJHI</pubmed_authors><pubmed_authors>Sharma L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Evaluation of short-acting Beta-2-agonist prescriptions and associated clinical outcomes: Findings from the SABA use IN Asthma (SABINA) study in Asia.</name><description>&lt;h4>Background&lt;/h4>The extent of short-acting Beta-2-agonist (β&lt;sub>2&lt;/sub>-agonist) (SABA) use across Asian countries is not well documented. As part of the SABA use IN Asthma (SABINA) III study, we assessed SABA prescriptions and clinical outcomes in patients with asthma from Asia.&lt;h4>Methods&lt;/h4>This cross-sectional study recruited patients (aged ≥12 years) with asthma from 8 Asian countries. Data on disease characteristics and asthma treatments were collected using electronic case report forms. Patients were classified by practice type (primary or specialist care) and investigator-defined asthma severity (per Global Initiative for Asthma [GINA] 2017 recommendations). The association of SABA prescriptions with clinical outcomes was analyzed using multivariable regression models.&lt;h4>Resu</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Oct</publication><modification>2026-06-02T18:57:39.3Z</modification><creation>2025-04-06T02:08:35.253Z</creation></dates><accession>S-EPMC10587767</accession><cross_references><pubmed>37869560</pubmed><doi>10.1016/j.waojou.2023.100823</doi></cross_references></HashMap>